TRIPS Waiver, MCIT, HR3. If you are not familiar with these policy developments, you probably should be.
The United States medtech and biotech industries make a tremendous impact on people’s lives. When policy makers and Federal Agencies work together, the impact is made even greater. However, some policy decisions can have the opposite effect.
Budget Also Invests In Public Health, Public Safety, Infrastructure And Wildfire PreventionContinue reading
The CMS rule the establishes a new coverage pathway – MCIT – for breakthrough medical technologies.
On December 4, 2020, the Biotechnology Innovation Organization (BIO), the California Life Sciences Association (CLSA), and BIOCOM California today filed a challenge against the Department of Health and Human Services’ (HHS) attempt, during the final days of the Trump Administration, to implement for the first time ever a “Most Favored Nation” reimbursement policy for certain drugs administered by Medicare Part B providers – drastically altering this system in ways that will harm their ability to serve America’s most vulnerable senior citizens.Continue reading
The 2020 Election Cycle has been historic and unique in many ways. As the sun rises on the 6th day after Election Day, here are some updates and resources to help you stay in the loop on what comes next.Continue reading
Statement from Dr. Michelle McMurry-Heath, President and CEO of the Biotechnology Innovation Organization (BIO)Continue reading
WASHINGTON, D.C. – The Advanced Medical Technology Association (AdvaMed) today announced availability of a newly created “Code of Ethics Compliance Guidance Related to the COVID-19 Response.”
“This guidance seeks to help AdvaMed members and other medical technology companies develop and implement processes that both support rapid decision-making in the context of the pandemic and mitigate any related compliance risks,” said Christopher L. White, AdvaMed COVID action team leader, chief operating officer and general counsel.Continue reading
On April 13, 2020, U.S. Representatives Eliot L. Engel (NY-16) and Fred Upton (MI-06), top Members of the Energy and Commerce Committee, led a bipartisan group of 181 House Members, including Arizona Representatives Andy Biggs, Ruben Gallego, Raul Grijalva, and Tom O’Halleran, in urging the Trump Administration to temporarily allow seniors to receive lifesaving drug infusions in their homes to prevent unnecessary trips to hospitals, which could potentially expose them to COVID-19.
Continue reading
The 2020 Arizona Legislative Session is in full swing. Take a look at what it can mean to you.Continue reading
Life Science leaders say two actions this week in Washington D.C. threaten to put life science innovation up against the ropes. Continue reading